Oncotarget

Reviews:

Targeting lipid metabolism in the treatment of ovarian cancer

Saliha Chaudhry, Stefani N. Thomas and Glenn E. Simmons Jr. _

PDF  |  Full Text  |  How to cite  |  Video Interview  |  Order a Reprint

Oncotarget. 2022; 13:768-783. https://doi.org/10.18632/oncotarget.28241

Metrics: PDF 699 views  |   Full Text 2725 views  |   ?  


Abstract

Saliha Chaudhry1, Stefani N. Thomas2 and Glenn E. Simmons Jr.3

1 Department of Medicine, University of Minnesota School of Medicine, Twin Cities, MN 55455, USA

2 Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Twin Cities, MN 55455, USA

3 Department of Biomedical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA

Correspondence to:

Glenn E. Simmons Jr., email: glenn.simmons@cornell.edu

Keywords: ovarian cancer; lipid metabolism; biomarkers; microenvironment; fatty acid

Received: July 05, 2021     Accepted: May 07, 2022     Published: May 25, 2022

Copyright: © 2022 Chaudhry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Cancer cells undergo alterations in lipid metabolism to support their high energy needs, tumorigenesis and evade an anti-tumor immune response. Alterations in fatty acid production are controlled by multiple enzymes, chiefly Acetyl CoA Carboxylase, ATP-Citrate Lyase, Fatty Acid Synthase, and Stearoyl CoA Desaturase 1. Ovarian cancer (OC) is a common gynecological malignancy with a high rate of aggressive carcinoma progression and drug resistance. The accumulation of unsaturated fatty acids in ovarian cancer supports cell growth, increased cancer cell migration, and worse patient outcomes. Ovarian cancer cells also expand their lipid stores via increased uptake of lipids using fatty acid translocases, fatty acid-binding proteins, and low-density lipoprotein receptors. Furthermore, increased lipogenesis and lipid uptake promote chemotherapy resistance and dampen the adaptive immune response needed to eliminate tumors. In this review, we discuss the role of lipid synthesis and metabolism in driving tumorigenesis and drug resistance in ovarian cancer conferring poor prognosis and outcomes in patients. We also cover some aspects of how lipids fuel ovarian cancer stem cells, and how these metabolic alterations in intracellular lipid content could potentially serve as biomarkers of ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28241